44 related articles for article (PubMed ID: 36045334)
1. Immunohistochemistry screening for TP53 mutation in myeloid neoplasms in AZF-fixed bone marrow biopsies.
Yang G; Anderson Williams S; He F; He Y; McIntyre K; Beckman AK; Nelson AC; Yohe SL
Pathology; 2024 Apr; 56(3):404-412. PubMed ID: 38341302
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical correlates of TP53 somatic mutations in cancer.
Murnyák B; Hortobágyi T
Oncotarget; 2016 Oct; 7(40):64910-64920. PubMed ID: 27626311
[TBL] [Abstract][Full Text] [Related]
3. Comparative Analysis of Primary Ovarian Cancer Cells and Established Cell Lines as a New Tool for Studies on Ovarian Cancer Cell Complexity.
Szyposzynska A; Bielawska-Pohl A; Paprocka M; Bar J; Murawski M; Klimczak A
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791431
[TBL] [Abstract][Full Text] [Related]
4. Clinical calculator based on CT and clinicopathologic characteristics predicts short-term prognosis following resection of microsatellite-stabilized diffuse gastric cancer.
Liu P; Ding P; Guo H; Yang J; Wu H; Wu J; Yang P; Zhao Q
Abdom Radiol (NY); 2024 May; ():. PubMed ID: 38727742
[TBL] [Abstract][Full Text] [Related]
5. CD10 Expression Correlates with Earlier Tumour Stages and Left-Sided Tumour Location in Colorectal Cancer but Has No Prognostic Impact in a European Cohort.
Grass JK; Grupp K; Kluth M; Hube-Magg C; Simon R; Kemper M; Izbicki JR; Sauter G; Melling N
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672555
[TBL] [Abstract][Full Text] [Related]
6. The spectrum of TP53 mutations in Rwandan patients with gastric cancer.
Nzitakera A; Surwumwe JB; Ndoricyimpaye EL; Uwamungu S; Uwamariya D; Manirakiza F; Ndayisaba MC; Ntakirutimana G; Seminega B; Dusabejambo V; Rutaganda E; Kamali P; Ngabonziza F; Ishikawa R; Rugwizangoga B; Iwashita Y; Yamada H; Yoshimura K; Sugimura H; Shinmura K
Genes Environ; 2024 Mar; 46(1):8. PubMed ID: 38459566
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the role of wound-healing genes in conjunction with stool routine and serum tumor markers for colorectal cancer diagnosis and prognostic implications.
Yu K; Fang X
Int Wound J; 2024 Mar; 21(3):e14768. PubMed ID: 38446012
[TBL] [Abstract][Full Text] [Related]
8. ZEB1 hypermethylation is associated with better prognosis in patients with colon cancer.
Fernandez-De-Los-Reyes I; Gomez-Dorronsoro M; Monreal-Santesteban I; Fernandez-Fernandez A; Fraga M; Azcue P; Alonso L; Fernandez-Marlasca B; Suarez J; Cordoba-Iturriagagoitia A; Guerrero-Setas D
Clin Epigenetics; 2023 Dec; 15(1):193. PubMed ID: 38093305
[TBL] [Abstract][Full Text] [Related]
9. Interplay of LncRNA TUG1 and TGF-β/P53 Expression in Colorectal Cancer.
Ibrahim BA; Gobran MA; Metwalli AM; Abd Elhady WA; Tolba AM; Omar WE
Asian Pac J Cancer Prev; 2023 Nov; 24(11):3957-3968. PubMed ID: 38019256
[TBL] [Abstract][Full Text] [Related]
10. Association of Chromosome 17 Aneuploidy,
Popek-Marciniec S; Styk W; Wojcierowska-Litwin M; Chocholska S; Szudy-Szczyrek A; Samardakiewicz M; Swiderska-Kolacz G; Czerwik-Marcinkowska J; Zmorzynski S
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835441
[TBL] [Abstract][Full Text] [Related]
11. Clinical, Pathological and Molecular Insights on KRAS, NRAS, BRAF, PIK3CA and TP53 Mutations in Metastatic Colorectal Cancer Patients from Northeastern Romania.
Afrăsânie VA; Marinca MV; Gafton B; Alexa-Stratulat T; Rusu A; Froicu EM; Sur D; Lungulescu CV; Popovici L; Lefter AV; Afrăsânie I; Ivanov AV; Miron L; Rusu C
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628868
[TBL] [Abstract][Full Text] [Related]
12. Case Report: Genetic and immune microenvironmental characteristics of a rectal cancer patient with MSS/PD-L1-negative recurrent hepatopulmonary metastasis who achieved complete remission after treatment with PD-1 inhibitor.
Song Y; Long J; Su X; Chen Z; He Y; Shao W; Wang B; Chen C
Front Immunol; 2023; 14():1197543. PubMed ID: 37520536
[TBL] [Abstract][Full Text] [Related]
13. p53/
Boldrin E; Piano MA; Bernaudo F; Alfieri R; Biasin MR; Montagner IM; Volpato A; Mattara G; Lamacchia F; Magni G; Rosato A; Scapinello A; Pilati P; Curtarello M
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345120
[TBL] [Abstract][Full Text] [Related]
14. Resistin-like beta reduction is associated to low survival rate and is downregulated by adjuvant therapy in colorectal cancer patients.
Di Rosa M; Di Cataldo A; Broggi G; Caltabiano R; Tibullo D; Castrogiovanni P; Imbesi R; Lanteri R; Salomone F; Raciti G; Li Volti G
Sci Rep; 2023 Jan; 13(1):1490. PubMed ID: 36707698
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of p53 protein expression and TP53 variation status in colorectal cancer.
Kim KM; Ahn AR; Park HS; Jang KY; Moon WS; Kang MJ; Ha GW; Lee MR; Chung MJ
BMC Cancer; 2022 Aug; 22(1):940. PubMed ID: 36045334
[TBL] [Abstract][Full Text] [Related]
16. Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients.
Manoharan V; Karunanayake EH; Tennekoon KH; De Silva S; Imthikab AIA; De Silva K; Angunawela P; Vishwakula S; Lunec J
BMC Cancer; 2020 Jan; 20(1):72. PubMed ID: 32000721
[TBL] [Abstract][Full Text] [Related]
17. The pattern-based interpretation of p53 immunohistochemical expression as a surrogate marker for TP53 mutations in colorectal cancer.
Osakabe M; Yamada N; Sugimoto R; Uesugi N; Nakao E; Honda M; Yanagawa N; Sugai T
Virchows Arch; 2024 Mar; ():. PubMed ID: 38512505
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
